TY - JOUR
T1 - Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions
T2 - A Subanalysis of the International, Multicenter GHOST-EU Registry
AU - Geraci, Salvatore
AU - Kawamoto, Hiroyoshi
AU - Caramanno, Giuseppe
AU - Ruparelia, Neil
AU - Capodanno, Davide
AU - Brugaletta, Salvatore
AU - Gori, Tommaso
AU - Nef, Holger
AU - Sabate, Manel
AU - Mehilli, Julinda
AU - Lesiak, Maciej
AU - Naber, Christoph
AU - Di Mario, Carlo
AU - Capranzano, Piera
AU - Wiebe, Jens
AU - Araszkiewicz, Aleksander
AU - Pyxaras, Stelios
AU - Mattesini, Alessio
AU - Münzel, Thomas
AU - Tamburino, Corrado
AU - Colombo, Antonio
AU - Latib, Azeem
N1 - Publisher Copyright:
© 2017
PY - 2017/3/27
Y1 - 2017/3/27
N2 - Objectives The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for “long coronary lesions.” Background The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. Methods The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm. Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Results Patients with lesions ≥60 mm had more comorbidities and more complex lesion characteristics, including chronic total occlusions (37%), bifurcation lesions (40.3%), higher Syntax score (16.4 ± 7.8), and higher number of scaffolds implanted per lesion (3.3 ± 0.9 mm). The main target vessel was the left anterior coronary artery in all groups. Median follow-up was 384 (interquartile range: 359 to 459) days. One-year follow-up was completed in 70.3% of patients. TLF at 1 year was significantly higher in group C (group A 4.8%, group B 4.5%, group C 14.3%; overall p = 0.001), whereas there were no significant differences between groups A and B. Finally, a numerically higher (but not statistically significant) number of scaffold thromboses were observed in group C when compared with shorter lesions (group A 2.1%, group B 1.1%, group C 3.8%; overall p = 0.29). Conclusions In a real-world setting, treatment of long coronary lesions with BVS ≥60 mm was associated with a higher TLF rate, driven by myocardial infarction and clinically driven target lesion revascularization.
AB - Objectives The authors sought to investigate 1-year outcomes in patients treated with bioresorbable everolimus-eluting vascular scaffolds (BVS) for “long coronary lesions.” Background The present substudy derived from the GHOST-EU registry included 1,722 lesions in 1,468 consecutive patients, enrolled between November 2011 and September 2014 at 11 European centers. Methods The lesions were divided into 3 groups according to continuous BVS length: 1) shorter than 30 mm; 2) between 30 and 60 mm; and 3) longer than 60 mm. Primary device-oriented endpoint (target lesion failure [TLF]) was defined as a combination of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Results Patients with lesions ≥60 mm had more comorbidities and more complex lesion characteristics, including chronic total occlusions (37%), bifurcation lesions (40.3%), higher Syntax score (16.4 ± 7.8), and higher number of scaffolds implanted per lesion (3.3 ± 0.9 mm). The main target vessel was the left anterior coronary artery in all groups. Median follow-up was 384 (interquartile range: 359 to 459) days. One-year follow-up was completed in 70.3% of patients. TLF at 1 year was significantly higher in group C (group A 4.8%, group B 4.5%, group C 14.3%; overall p = 0.001), whereas there were no significant differences between groups A and B. Finally, a numerically higher (but not statistically significant) number of scaffold thromboses were observed in group C when compared with shorter lesions (group A 2.1%, group B 1.1%, group C 3.8%; overall p = 0.29). Conclusions In a real-world setting, treatment of long coronary lesions with BVS ≥60 mm was associated with a higher TLF rate, driven by myocardial infarction and clinically driven target lesion revascularization.
KW - bioresorbable vascular scaffolds
KW - complex coronary lesions
KW - long coronary lesions
KW - vascular reparative therapy
UR - http://www.scopus.com/inward/record.url?scp=85014127277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014127277&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2016.12.013
DO - 10.1016/j.jcin.2016.12.013
M3 - Article
C2 - 28259663
AN - SCOPUS:85014127277
SN - 1936-8798
VL - 10
SP - 560
EP - 568
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 6
ER -